| 美罗华联合Hyper-CVAD/MTX+Ara-C方案治疗高危青年伯基特淋巴瘤的疗效观察(附6例) |
| |
| 引用本文： | 周 倩,阿茹娜.美罗华联合Hyper-CVAD/MTX+Ara-C方案治疗高危青年伯基特淋巴瘤的疗效观察(附6例)[J].现代肿瘤医学,2020,0(14):2490-2493. |
| |
| 作者姓名： | 周 倩 阿茹娜 |
| |
| 作者单位： | 内蒙古自治区人民医院血液内科，内蒙古 呼和浩特 010017 |
| |
| 基金项目： | 内蒙古自治区自然科学基金项目(编号:2018MS08070) |
| |
| 摘 要： | 目的:分析美罗华联合Hyper-CVAD/MTX+Ara-C方案治疗高危青年伯基特淋巴瘤的治疗效果。方法:总结2014年10月至2016年10月,我院收治的6例伯基特淋巴瘤患者的特征,均采用美罗华联合Hyper-CVAD/MTX+Ara-C方案化疗,历时4个周期共8个疗程,病程中腰穿及鞘注。结果:6例初诊患者临床分期(Arbor分期)Ⅲ期1例,Ⅳ期5例;首发部位多见于腹部包块及浅表淋巴结,均有B症状,乳酸脱氢酶(LDH)水平偏高,骨髓侵犯3例,中枢神经系统侵犯1例,有结外侵犯者3例。总疗程结束后评估,CR 5例,PR 1例,平均缓解期2.3个月。随访2.5年,5例患者病情稳定,1例死亡。结论:美罗华联合Hyper-CVAD/MTX+Ara-C方案治疗高危青年伯基特淋巴瘤有一定效果,患者对联合化疗的耐受性尚可。
|
| 关 键 词： | 伯基特淋巴瘤 美罗华 Hyper-CVAD/MTX+Ara-C方案 效果 |
Observation on the efficacy of rituximab combined with Hyper-CVAD/MTX+Ara-C regimen in the treatment of 6 cases of high-risk young Burkitt lymphoma |
| |
| Zhou Qian,Aruna.Observation on the efficacy of rituximab combined with Hyper-CVAD/MTX+Ara-C regimen in the treatment of 6 cases of high-risk young Burkitt lymphoma[J].Journal of Modern Oncology,2020,0(14):2490-2493. |
| |
| Authors: | Zhou Qian Aruna |
| |
| Affiliation: | Department of Hematology,Inner Mongolia People's Hospital,Inner Mongolia Hohhot 010017,China. |
| |
| Abstract: | Objective:To analyse the therapeutic effect of rituximab combined with Hyper-CVAD/MTX+Ara-C regimen in the treatment of high-risk young Burkitt lymphoma.Methods:To summarize the characteristics of 6 patients with Burkitt lymphoma treated in hospital from October 2014 to October 2016，rituximab combined with Hyper-CVAD/MTX+Ara-C regimen was used in all patients， which total of 8 courses of treatment lasted 4 cycles.Lumbar puncture and sheath injection were used.Results:Clinical staging（Arbor staging) of 6 newly diagnosed patients:1 case in stage Ⅲ and 5 cases in stage Ⅳ.The primary site was abdominal mass and superficial lymph nodes,all with B symptoms，high lactate dehydrogenase,bone marrow invasion in 3 cases,central nervous system invasion in 1 case，3 cases with extranodal invasion.There were 5 cases with CR and 1 case with PR,with an average median remission period of 2.3 months.Follow-up of 2.5 years showed that 5 patients were in stable condition and 1 was died.Conclusion:Rituximab combined with Hyper-CVAD/MTX+Ara-C regimen has a certain effect in the treatment of high-risk young Burkitt lymphoma,and the patient's tolerance to combined chemotherapy is acceptable. |
| |
| Keywords: | Burkitt lymphoma rituximab Hyper-CVAD/MTX+Ara-C regimen effect |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
|
